M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway

Scandinavian Journal of Immunology

Volumn 85, Issue 2, 2017, Pages 122-129

  Aletaha, S ^a   Haddad, L ^b   Roozbehkia, M ^a   Bigdeli, R ^c,d   Asgary, V ^a   Mahmoudi, M ^a   Mirshafiey, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MANNURONIC ACID; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; HEXURONIC ACID; MYD88 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL PEPTIDE; TOLLIP PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; EMBRYO; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEK293 CELLS; HEXURONIC ACIDS; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85014993311     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12519     Document Type: Article

References (34)

1. Slak JL, Schooley K, Bonnert TP et al. Identification of two major sites in the type ɪ interleukin-1 receptor cytoplasmic region responsible for coupling to proinflammatory signaling pathways. J Biol Chem 2000;275 :4670–8.
2. Pandey S, Kawai T, Akira S. Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb Perspect Biol 2014;7:a016246.
3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140 :805–20.
4. Guerrier T, Pochard P, Lahiri A, Youinou P, Pers JO, Jamin C. TLR9 expressed on plasma membrane acts as negative regulator of human B cell response. J Autoimmun 2014;51:23–9.
5. Onji M, Kanno A, Saitoh S et al. TLR9 is expressed on the surface of splenic DCs: an essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun 2013;4:1949.
6. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010;42 :495–505.
7. Cognasse F, Nguyen KA, Damien P et al. The inflammatory role of platelets via their TLRs and siglec receptors. Front Immunol 2015;6:83.
8. Jang S, Park JS, Won YH, Yun SJ, Kim SJ. The expression of Toll-Like Receptors (TLRs) in cultured human skin fibroblast is modulated by histamine. Chonnam Med J 2012;48 :7–14.
9. Pandolfi F, Altamura S, Frosail S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. Clin Ther 2016;38 :1017–28.
10. Oliveira-Nascimento L, Massari P, Wetzler LM. The role of TLR2 in infection and immunity. Front Immunol 2012;3:79.
11. Jin MS, Kim SE, Heo JY et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130 :1071–82.
12. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19 :3–10.
13. Nagai Y, Akashi S, Nagafuku M et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3 :667–72.
14. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014;5:461.
15. Lin SC, Lo YC, Wu H. Helical assembly in the Myd88-IRAK4-IRAK2 complex in TLR/IL-1R signaling. Nature 2010;465 :885–90.
16. Zhang G, Ghosh S. Negative regulation of Toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277 :7059–65.
17. Didierlaurent A, Brissoni B, Velin D et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol 2006;26 :735–42.
18. De Jaqer PL, Franchimont D, Waliszewska A et al. the role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007;8 :387–97.
19. Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol 2014;47 :136–47.
20. Opal SM, Laterre PF, Francois B et al. Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients with Severe SepsisThe ACCESS Randomized TrialEritoran for the Treatment of Severe sepsis. JAMA 2013;309 :1154–62.
21. Matsunaga N, Tsuchimori N, Matsumoto T, Li M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011;79:34–41.
22. Mirshafiey A, Cuzzocrea S, Rehm B, Mazzon E, Saadat F, Sotoude M. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol 2005;61 :435–41.
23. Mirshafiey A, Matsuo H, Nakane S, Rehm BH, Koh CS, Miyoshi S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 2005;27 :255–65.
24. Mirshafiey A, Rehm BH, Sahmani A, Naji A, Razavi A. M2000, as a New Anti-inflammatory Molecule in Treatment of Experimental Nephrosis. Immunopharmacol Immunotoxicol 2004;26 :611–9.
25. Mirshafiey A, Rehm B, Abhari RS, Borzooy Z, Sotoude M, Razavi A. Production of M2000 (beta-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 2007;24 :60–6.
26. Fattahi MJ, Abdollahi M, Agha Mohammadi A et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 2015;37 :535–40.
27. Wang Z, Macleod DT, Di Nardo A. Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses. J Immunol 2012;189 :1551–8.
28. He W, Wang Z, Zhou Z et al. Lipopolysaccharide enhances Wnt5a expression through toll-like receptor 4, myeloid differentiating factor 88, phosphatidylinositol 3-OH kinase/AKT and nuclear factor kappa B pathways in human dental pulp stem cell. J Endod 2014;40 :69–75.
29. Flo TH, Ryan L, Latz E et al. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymer. J Biol Chem 2002;277: 35489–95.
30. Flo TH, Liv R, Kilaas L et al. Involvement CD14 and β2-Integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun 2000;68:6770–6.
31. Iwamato M, Kurachi M, Nakashima T et al. Structure-activity relationship of alginate oligosaccharides in the induction of cytokine production from RAW264.7 cells. FEBS Lett 2005;579: 4423–9.
32. Xu R, Jiang ZH. Synthesis of beta-(1→4)-oligo-D-mannuronic acid neoglycolipids. Carbohydr Res 2008;343 :7–17.
33. Silvka P, Shridhar M, Lee GI et al. A peptide antagonist of the TLR4-MD2 interaction. Combiochem 2009;10:645–9.
34. Kalluri MD, Datla P, Bellary A et al. Novel synthetic gluco-disaccharide RSCL-0409-a lipopolysaccharide-induced Toll-like receptor-mediated signaling antagonist. FEBS J 2010;277 :1639–52.